– Additional Commitment will Expand Access to Lenacapavir to Reach Another Million People Over the Next 3 Years–

Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. State Department, the United States President's Emergency Plan for AIDS Relief (PEPFAR) and The Global Fund will further invest in Gilead's twice-yearly injectable HIV prevention medicine, lenacapavir, to expand access for up to an additional 1 million people, bringing the total commitment up to 3 million people in high-incidence, resource-limited countries through 2028.

Bringing together the resources and expertise of both PEPFAR and The Global Fund is a key component of Gilead's larger coordinated efforts to advance access to lenacapavir for HIV PrEP. These partners are experts in country delivery and distribution, with the reach and infrastructure to ensure these supplies reach those with the greatest need as quickly as possible. Lenacapavir is the first HIV prevention therapy to reach communities in sub-Saharan Africa in the same year it was approved in the United States, with initial shipments arriving at the end of 2025.